Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Total Non-Current Liabilities (2020 - 2025)

Biofrontera has reported Total Non-Current Liabilities over the past 6 years, most recently at $17.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 8.01% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $17.7 million, up 8.01%, while the annual FY2025 figure was $17.7 million, 8.01% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $17.7 million at Biofrontera, up from $17.2 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $36.2 million in Q4 2021 and troughed at -$8.6 million in Q2 2023.
  • A 5-year average of $20.1 million and a median of $21.2 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 130.38% in 2023 and later skyrocketed 213.11% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $36.2 million in 2021, then decreased by 25.52% to $27.0 million in 2022, then dropped by 29.85% to $18.9 million in 2023, then decreased by 13.27% to $16.4 million in 2024, then rose by 8.01% to $17.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BFRI at $17.7 million in Q4 2025, $17.2 million in Q3 2025, and $24.3 million in Q2 2025.